Personalized Cancer Vaccine Stops Melanoma's Return

Imagine a cancer vaccine custom-built just for you, trained to hunt down your specific tumor cells before they can return. That future just got a lot closer.

Moderna and Merck announced this week that their personalized melanoma vaccine, intismeran, successfully kept cancer from coming back in patients with advanced skin cancer. The breakthrough marks a major step toward FDA approval and could change how we fight cancer forever.

Here's how it works. After a patient's melanoma tumor is removed, scientists spend about six weeks creating a custom vaccine based on that person's unique cancer cells. They sequence the tumor's genetic code to find special proteins called neoantigens that sit on the surface of cancer cells.

The vaccine uses the same mRNA technology that powered Covid-19 vaccines, but instead of fighting a virus, it trains your immune system to recognize and destroy any cancer cells that try to come back.

The trial included 1,137 patients whose advanced melanoma had been surgically removed but was likely to return. Half received the personalized vaccine plus an immunotherapy drug called pembrolizumab, while the other half got the drug alone.

Patients who received both treatments lived significantly longer without their cancer returning. They also went longer without developing new tumors in other parts of the body.

The companies haven't released detailed numbers yet but called the results "clinically meaningful." Earlier this year, they reported that a mid-stage trial showed the combination reduced melanoma's return by 49 percent after five years.

Melanoma kills an estimated 8,510 Americans every year. While it's highly treatable when caught early, advanced melanoma that has spread deeper into the skin or to other organs remains difficult to cure.

The Ripple Effect

Scientists say this breakthrough could extend far beyond melanoma. Researchers are already developing personalized mRNA vaccines for pancreatic, stomach, kidney, bladder, colon and lung cancers.

"What might have been considered science fiction 15 or 20 years ago could be used to delay progression of melanoma," Jedd Wolchok, director of the Meyer Cancer Center at Weill Cornell Medicine, told STAT. "It really establishes personalized cancer vaccines as being a new addition to standard cancer therapy."

The approach could even help treat rare genetic conditions. Because the technology can be customized to target any unique mutation, experts believe it opens doors to treating diseases we've struggled with for generations.

Robert Vonderheide, director of Penn Medicine's Abramson Cancer Center, expects to see results from multiple similar studies over the next few years, and there's every reason to hope many will be positive.

A personalized weapon against cancer, one patient at a time, is no longer science fiction.